Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19.

ABSTRACT:

Objective

We are still in search of new therapeutic options for COVID-19 to prevent new infections, enable fast recovery, and reduce the long-lasting symptoms or sequelae. This study aimed to investigate the short- and long-term effects of inhaled aviptadil on hospitalized, adult COVID-19 patients.

Methods

A multicenter, prospective, placebo-controlled, comparative, randomized, double-blind clinical trial was conducted. Patients were randomized 1:1 to either inhaled aviptadil or placebo, in addition to the standard care. The primary endpoint is the time from hospitalization to discharge within 30 days of treatment. The secondary endpoints are clinical and radiological score improvements.

Results

The study involved 80 patients enrolled from 9 clinical centers. The mean

SUBMITTER: Esendagli D 

PROVIDER: S-EPMC11936437 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature